Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma

(MedPage Today) -- Data presented at the 2023 American Society of Hematology (ASH) annual meeting demonstrated that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) significantly...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news